Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure

被引：0

作者：

Grandal, Marta ^{[1
]}

Pernas, Berta ^{[1
]}

Marino, Ana ^{[2
]}

Alvarez, Hortensia ^{[2
]}

Tabernilla, Andres ^{[1
]}

Castro-Iglesias, Angeles ^{[1
]}

Mena, Alvaro ^{[1
]}

Delgado, Manuel ^{[1
]}

Pertega, Sonia ^{[3
]}

Poveda, Eva ^{[1
]}

机构：

[1] SERGAS Univ A Coruna, CHUAC, Inst Invest Biomed A Coruna INIBIC, Grp Virol Clin, La Coruna, Spain

[2] CHUF, SERGAS, Unidad Enfermedades Infecciosas, Serv Med Interna, Ferrol, Spain

[3] CHUAC, Inst Invest Biomed A Coruna INIIBC, Unidad Epidemiol Clin & Bioestadist, La Coruna, Spain

来源：

JOURNAL OF MEDICAL VIROLOGY | 2017年 / 89卷 / 07期

关键词：

HCV infection; HCV treatment; HIV/HCV coinfection; HEPATITIS-C VIRUS; NATURAL-HISTORY; REAL-WORLD; EPIDEMIOLOGY; METAANALYSIS; COINFECTION; GENOTYPES; HIV/HCV; EUROPE; TIME;

D O I：

10.1002/jmv.24766

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected and 28.2% cirrhotic). Of these, 72.9% of patients that were recognized as priority for HCV treatment according to the Spanish Strategic Plan (>= F2, transplant or extrahepatic manifestations), initiated treatment during 2015. Globally, SVR12 was achieved in 96.5% of patients. The implementation of the Spanish Strategic Plan has been critical to advance in HCV cure, but 27.1% of priority patients still remain awaiting HCV treatment initiation.

引用

页码：1304 / 1308

页数：5

共 4 条

[1] Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Roguljic, Hrvoje
Nincevic, Vjera
Bojanic, Kristina
Kuna, Lucija
Smolic, Robert
Vcev, Aleksandar
Primorac, Dragan
Vceva, Andrijana
Wu, George Y.
Smolic, Martina
FRONTIERS IN PHARMACOLOGY, 2021, 12
[2] Management and Treatment of Chronic HBV and HCV Co-Infection and the Impact of Anti-Viral Therapy
Mitchell L. Shiffman
Nadege T. Gunn
Current Hepatology Reports, 2017, 16 (3) : 169 - 177
[3] Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
Dash, Srikanta
Aydin, Yucel
Widmer, Kyle E.
Nayak, Leela
JOURNAL OF HEPATOCELLULAR CARCINOMA, 2020, 7 : 45 - 76
[4] Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis
Rattanavipapong, Waranya
Anothaisintawee, Thunyarat
Teerawattananon, Yot
PLOS ONE, 2018, 13 (02):

← 1 →